—QOL-B Respiratory Domain Shown to Work
Effectively as Patient-Reported Outcome Tool in Patients
with MAC Lung Disease; to be Proposed to FDA as Primary Endpoint in
ENCORE with No Modifications—
—Patients Treated with ARIKAYCE Plus
Macrolide-Based Background Regimen Had Meaningfully Larger
Improvements in QOL-B Respiratory Score with Strong Trend Toward
Significance vs. Macrolide-Based Background Regimen
Alone—
—ARIKAYCE-Treated Patients Had Nominally
Statistically Significantly Higher Culture Conversion Rates at
Month 7 vs. Comparator (78.8% vs. 47.1%, p=0.0010); Culture
Conversion Began Earlier and Was More Likely to Persist Through
Month 7 with ARIKAYCE Regimen—
—No New or Unexpected Safety Signals
Observed—
—Insmed to Explore Accelerating Filing for
ARIKAYCE in Newly Infected MAC Lung Disease Patients with Global
Regulators on Basis of ARISE Data—
—Insmed to Host Investor Call at 8:30 a.m. ET on Tuesday, September 5—
BRIDGEWATER, N.J., Sept. 5,
2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:
INSM), a global biopharmaceutical company on a mission to transform
the lives of patients with serious and rare diseases, today
announced positive topline results from its Phase 3 ARISE study of
ARIKAYCE in patients with newly diagnosed or recurrent
nontuberculous mycobacterial (NTM) lung infection caused by
Mycobacterium avium complex (MAC) who had not started
antibiotics.
The study met its primary objective of demonstrating that the
Quality of Life – Bronchiectasis (QOL-B) respiratory domain works
effectively as a patient-reported outcome (PRO) instrument in
patients with MAC lung disease. Based on these results, Insmed
plans to propose to the U.S. Food and Drug Administration (FDA)
that the QOL-B respiratory domain PRO be the primary endpoint for
the ENCORE study without any modifications.
Patients in ARISE (N=99) were randomized 1:1 to treatment with
ARIKAYCE plus macrolide-based background regimen (ARIKAYCE arm) or
placebo plus macrolide-based background regimen (comparator arm)
for six months, followed by one month off treatment.
ARIKAYCE-treated patients performed better than those in the
comparator arm as measured by the QOL-B instrument, with 43.8% of
patients achieving an improvement in QOL-B respiratory score above
the estimated meaningful within-subject score difference of 14.8,
compared with 33.3% of patients in the comparator arm. While the
study was not powered to show a statistically significant
difference between treatment arms, a strong trend toward
significance was observed for improvement from baseline at Month 7
(12.24 vs. 7.76, p=0.1073).
Patients in the ARIKAYCE arm also achieved nominally
statistically significantly higher culture conversion rates at
Month 7 versus patients in the comparator arm (78.8% vs. 47.1%,
p=0.0010), and culture conversion was faster and more likely to
persist through Month 7 for the ARIKAYCE arm.
"The ARISE study represents a clear and unambiguous win for the
entire NTM community. We are thrilled that these results not only
validate a PRO tool in NTM lung disease, but also show that
patients treated with an ARIKAYCE-based regimen felt better versus
patients in the comparator arm, as measured by this instrument.
Coupled with extraordinary culture conversion outcomes, these
findings give us great confidence that our Phase 3 registrational
trial, ENCORE, is well-positioned to achieve both statistically and
clinically meaningful results, leading to a sizeable increase in
the number of patients who could hope to benefit from ARIKAYCE,"
said Martina Flammer, M.D., MBA,
Chief Medical Officer of Insmed.
Based on the results of ARISE, Insmed plans to explore with
global regulators accelerating the filing for approval of ARIKAYCE
in newly infected patients with MAC lung disease. In parallel, the
Company continues to enroll patients in ENCORE, which will use the
PRO tool that has been validated in ARISE, with 250 patients
expected to be enrolled by the end of 2023. Enrollment in ENCORE is
expected to continue into 2024 to ensure a high degree of
statistical powering and Insmed anticipates reporting topline data
from ENCORE in 2025.
"I want to thank the many patients, caregivers, and
investigators who participated in ARISE and made this impressive
outcome possible. We look forward to discussing these excellent
results from this well-executed study in the near future with
regulators," noted Kevin Mange, M.D., M.S.C.E., Chief Development
Officer of Insmed.
Additional ARISE Study Findings
Insmed reported the following additional results from the ARISE
study:
Culture Conversion
Consistent with prior clinical
studies, a higher proportion of patients in the ARIKAYCE arm
achieved culture conversion by Month 6 (defined as negative
cultures at Months 5 and 6) compared to patients in the comparator
arm (80.6% vs. 63.9%, p=0.0712). Among patients who achieved
culture conversion by Month 6, more patients in the ARIKAYCE arm
achieved the first of their two required monthly negative cultures
for clinical conversion at Month 1 versus the comparator arm (74.3%
vs. 46.7%). As reported above, at Month 7 (one month following the
cessation of treatment), 47.1% of patients in the comparator arm
were culture-converted vs. 78.8% of patients in the ARIKAYCE arm,
suggesting that ARIKAYCE-treated patients are more likely to remain
negative.
Correlation Between Culture Conversion and QOL-B
Performance
Patients in the ARIKAYCE arm who achieved
culture conversion at both Month 6 and Month 7 had nominally
statistically significantly greater improvements in QOL-B
respiratory domain scores at Month 7 compared to patients in the
ARIKAYCE arm who did not achieve culture conversion (15.74 vs.
3.53, p=0.0167 at Month 6 and 14.89 vs. 4.50, p=0.0416 at Month
7).
PROMIS Fatigue-Short Form 7a
The Patient-Reported
Outcome Measurement Information System (PROMIS) Fatigue-Short Form
7a was also assessed in the study. While both treatment arms showed
improvements in the PROMIS Fatigue scores from Baseline to Month 7,
the difference between treatment groups was not significant, with
35.5% of ARIKAYCE patients achieving a within-subject meaningful
difference of at least a 4-unit decrease (a negative change
signifies improvement) compared to 29.4% of subjects in the
comparator arm. As previously noted, the study was not powered to
show a statistically significant difference between treatment
arms.
Safety and Tolerability
The discontinuation rate of
ARIKAYCE or the placebo used in the comparator arm was 22.9% in the
ARIKAYCE arm and 7.8% in the comparator arm. Study completion rates
were 91.7% in the ARIKAYCE arm and 94.1% in the comparator arm. No
new safety events were observed in the ARIKAYCE arm, and the safety
profile in general was as expected in both treatment arms.
Treatment-emergent adverse events (TEAEs) were reported by 91.7% of
patients in the ARIKAYCE arm and 80.4% of patients in the
comparator arm. The most common TEAEs were dysphonia (41.7% for the
ARIKAYCE arm vs. 3.9% for the comparator arm), cough (27.1% vs.
7.8%), diarrhea (27.1% vs. 25.5%), and COVID-19 (12.5% vs. 9.8%).
Of the treatment-emergent serious adverse events observed in the
trial, none were determined to be related to ARIKAYCE by
investigators and none were deemed related to COVID-19.
About the ARISE & ENCORE Clinical Trial Program
ARIKAYCE was granted accelerated approval by the FDA in
September of 2018 for the treatment of MAC lung disease as part of
a combination antibacterial drug regimen for adult patients who
have limited or no alternative treatment options. It is the first
and only therapy approved in the U.S. for the treatment of MAC lung
disease. The ARISE and ENCORE clinical trial program is intended to
fulfill the FDA's post-marketing requirement to allow for full
approval of ARIKAYCE in the U.S. and to support a supplemental new
drug application for the use of ARIKAYCE as a treatment for
patients with a MAC lung infection.
ARISE was a global, randomized, double-blind,
placebo-controlled, Phase 3b study in
adult patients with newly diagnosed or recurrent MAC lung disease
who had not started antibiotics that aimed to generate evidence
demonstrating the domain specification, reliability, validity, and
responsiveness of PRO-based scores. Patients were randomized 1:1 to
receive ARIKAYCE plus background regimen or placebo plus background
regimen once daily for six months. Patients then discontinued all
study treatments and remained in the trial for one month for the
continued assessment of PRO endpoints. The study enrolled 99
patients.
The ongoing ENCORE trial is a randomized, double-blind,
placebo-controlled, Phase 3b study to
evaluate the efficacy and safety of an ARIKAYCE-based regimen in
patients with newly diagnosed or recurrent MAC lung disease who
have not started antibiotics. Patients are randomized 1:1 to
receive ARIKAYCE plus background regimen or placebo plus background
regimen once daily for 12 months. Patients will then discontinue
all study treatments and remain in the trial for three months for
the assessment of durability of culture conversion. The primary
endpoint is change from Baseline to Month 13 in respiratory symptom
score. The key secondary endpoint is the proportion of patients
achieving durable culture conversion at Month 15.
About the Validation of PRO Tools in MAC Lung Disease
Today, there are no established clinical endpoints to evaluate
the benefits of treatment in patients with MAC lung disease. The
QOL-B instrument is a self-administered PRO questionnaire used to
assess symptoms, functioning, and health-related quality of life in
adults with non-cystic fibrosis bronchiectasis. Insmed's clinical
trial program to establish that the Respiratory Symptom Domain of
the QOL-B is reliable for measuring respiratory symptoms in
patients with MAC lung disease generated evidence to support
content validity based on concept elicitation and cognitive
interviews with patients, and generated evidence to support
measurement properties based on cross-sectional analyses using
screening and baseline blinded data from both ARISE and a subset of
patients from ENCORE (first 131 patients enrolled). Longitudinal
analyses were based on ARISE data. Researchers used the Patient
Global Impression of Severity (PGI-S) questionnaire, a simple,
one-question categorical rating of symptom severity, as an anchor
to estimate a range of meaningful within-subject score differences.
The PROMIS Fatigue Short Form 7a was also evaluated in this
clinical trial program using an identical approach.
Conference Call
Insmed management will host a
conference call for investors beginning at 8:30 a.m. ET on
Tuesday, September 5, 2023, to
discuss the ARISE results. Shareholders and other interested
parties may participate in the conference call by dialing (888)
210-2654 (U.S. and international) and referencing access code
7862189. The call will also be webcast live on the Company's
website at www.insmed.com.
A replay of the conference call will be accessible approximately
one hour after its completion through October 5, 2023, by
dialing (800) 770-2030 (U.S. and international) and referencing
access code 7862189. A webcast of the call will also be archived
for 90 days under the Investor Relations section of the Company's
website at www.insmed.com.
About MAC Lung Disease
Mycobacterium
avium complex (MAC) lung disease is a rare and serious
disorder that can significantly increase morbidity and mortality.
Patients with MAC lung disease can experience a range of symptoms
that often worsen over time, including chronic cough, dyspnea,
fatigue, fever, weight loss, and chest pain. In some cases, MAC
lung disease can cause severe, even permanent damage to the lungs,
and can be fatal. MAC lung disease is an emerging public health
concern worldwide with significant unmet need.
About ARIKAYCE
ARIKAYCE is approved in the United
States as ARIKAYCE® (amikacin liposome
inhalation suspension), in Europe as
ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion,
and in Japan as ARIKAYCE® inhalation 590
mg (amikacin sulfate inhalation drug product). Current
international treatment guidelines recommend the use of ARIKAYCE
for appropriate patients. ARIKAYCE is a novel, inhaled, once-daily
formulation of amikacin, an established antibiotic that was
historically administered intravenously and associated with severe
toxicity to hearing, balance, and kidney function. Insmed's
proprietary PULMOVANCE® liposomal technology
enables the delivery of amikacin directly to the lungs, where
liposomal amikacin is taken up by lung macrophages where the
infection resides, while limiting systemic exposure. ARIKAYCE is
administered once daily using the Lamira® Nebulizer
System manufactured by PARI Pharma GmbH (PARI).
About PARI Pharma and the Lamira® Nebulizer
System
ARIKAYCE is delivered by a novel inhalation device,
the Lamira® Nebulizer System, developed by PARI.
Lamira® is a quiet, portable nebulizer that enables
efficient aerosolization of ARIKAYCE via a vibrating, perforated
membrane. Based on PARI's 100-year history working with aerosols,
PARI is dedicated to advancing inhalation therapies by developing
innovative delivery platforms to improve patient care.
IMPORTANT SAFETY INFORMATION FOR ARIKAYCE IN THE U.S.
WARNING: RISK OF
INCREASED RESPIRATORY ADVERSE REACTIONS
ARIKAYCE has been
associated with an increased risk of respiratory adverse reactions,
including hypersensitivity pneumonitis, hemoptysis, bronchospasm,
and exacerbation of underlying pulmonary disease that have led to
hospitalizations in some cases.
|
Hypersensitivity Pneumonitis has been reported
with the use of ARIKAYCE in the clinical trials. Hypersensitivity
pneumonitis (reported as allergic alveolitis, pneumonitis,
interstitial lung disease, allergic reaction to ARIKAYCE) was
reported at a higher frequency in patients treated with ARIKAYCE
plus background regimen (3.1%) compared to patients treated with a
background regimen alone (0%). Most patients with hypersensitivity
pneumonitis discontinued treatment with ARIKAYCE and received
treatment with corticosteroids. If hypersensitivity pneumonitis
occurs, discontinue ARIKAYCE and manage patients as medically
appropriate.
Hemoptysis has been reported with the use of
ARIKAYCE in the clinical trials. Hemoptysis was reported at a
higher frequency in patients treated with ARIKAYCE plus background
regimen (17.9%) compared to patients treated with a background
regimen alone (12.5%). If hemoptysis occurs, manage patients
as medically appropriate.
Bronchospasm has been reported with the use of
ARIKAYCE in the clinical trials. Bronchospasm (reported as asthma,
bronchial hyperreactivity, bronchospasm, dyspnea, dyspnea
exertional, prolonged expiration, throat tightness, wheezing) was
reported at a higher frequency in patients treated with ARIKAYCE
plus background regimen (28.7%) compared to patients treated
with a background regimen alone (10.7%). If bronchospasm occurs
during the use of ARIKAYCE, treat patients as medically
appropriate.
Exacerbations of underlying pulmonary disease has
been reported with the use of ARIKAYCE in the clinical trials.
Exacerbations of underlying pulmonary disease (reported as chronic
obstructive pulmonary disease (COPD), infective exacerbation of
COPD, infective exacerbation of bronchiectasis) have been reported
at a higher frequency in patients treated with ARIKAYCE plus
background regimen (14.8%) compared to patients treated with
background regimen alone (9.8%). If exacerbations of
underlying pulmonary disease occur during the use of ARIKAYCE,
treat patients as medically appropriate.
Anaphylaxis and Hypersensitivity Reactions: Serious
and potentially life-threatening hypersensitivity reactions,
including anaphylaxis, have been reported in patients taking
ARIKAYCE. Signs and symptoms include acute onset of skin and
mucosal tissue hypersensitivity reactions (hives, itching,
flushing, swollen lips/tongue/uvula), respiratory difficulty
(shortness of breath, wheezing, stridor, cough), gastrointestinal
symptoms (nausea, vomiting, diarrhea, crampy abdominal pain), and
cardiovascular signs and symptoms of anaphylaxis (tachycardia, low
blood pressure, syncope, incontinence, dizziness). Before therapy
with ARIKAYCE is instituted, evaluate for previous hypersensitivity
reactions to aminoglycosides. If anaphylaxis or a hypersensitivity
reaction occurs, discontinue ARIKAYCE and institute appropriate
supportive measures.
Ototoxicity has been reported with the use of
ARIKAYCE in the clinical trials. Ototoxicity (including deafness,
dizziness, presyncope, tinnitus, and vertigo) were reported with a
higher frequency in patients treated with ARIKAYCE plus background
regimen (17%) compared to patients treated with background
regimen alone (9.8%). This was primarily driven by tinnitus
(7.6% in ARIKAYCE plus background regimen vs 0.9% in the background
regimen alone arm) and dizziness (6.3% in ARIKAYCE plus background
regimen vs 2.7% in the background regimen alone arm). Closely
monitor patients with known or suspected auditory or vestibular
dysfunction during treatment with ARIKAYCE. If ototoxicity occurs,
manage patients as medically appropriate, including potentially
discontinuing ARIKAYCE.
Nephrotoxicity was observed during the clinical
trials of ARIKAYCE in patients with MAC lung disease but not at a
higher frequency than background regimen alone. Nephrotoxicity has
been associated with the aminoglycosides. Close monitoring of
patients with known or suspected renal dysfunction may be needed
when prescribing ARIKAYCE.
Neuromuscular Blockade: Patients with
neuromuscular disorders were not enrolled in ARIKAYCE clinical
trials. Patients with known or suspected neuromuscular disorders,
such as myasthenia gravis, should be closely monitored since
aminoglycosides may aggravate muscle weakness by blocking the
release of acetylcholine at neuromuscular junctions.
Embryo-Fetal Toxicity: Aminoglycosides can
cause fetal harm when administered to a pregnant woman.
Aminoglycosides, including ARIKAYCE, may be associated with total,
irreversible, bilateral congenital deafness in pediatric patients
exposed in utero. Patients who use ARIKAYCE during
pregnancy or become pregnant while taking ARIKAYCE should be
apprised of the potential hazard to the fetus.
Contraindications: ARIKAYCE is contraindicated in
patients with known hypersensitivity to any aminoglycoside.
Most Common Adverse Reactions: The most common
adverse reactions in Trial 1 at an incidence ≥5% for patients using
ARIKAYCE plus background regimen compared to patients treated with
background regimen alone were dysphonia (47% vs 1%), cough (39% vs
17%), bronchospasm (29% vs 11%), hemoptysis (18% vs 13%),
ototoxicity (17% vs 10%), upper airway irritation (17% vs 2%),
musculoskeletal pain (17% vs 8%), fatigue and asthenia (16% vs
10%), exacerbation of underlying pulmonary disease (15% vs 10%),
diarrhea (13% vs 5%), nausea (12% vs 4%), pneumonia (10% vs 8%),
headache (10% vs 5%), pyrexia (7% vs 5%), vomiting (7% vs 4%), rash
(6% vs 2%), decreased weight (6% vs 1%), change in sputum (5% vs
1%), and chest discomfort (5% vs 3%).
Drug Interactions: Avoid concomitant use of
ARIKAYCE with medications associated with neurotoxicity,
nephrotoxicity, and ototoxicity. Some diuretics can enhance
aminoglycoside toxicity by altering aminoglycoside concentrations
in serum and tissue. Avoid concomitant use of ARIKAYCE with
ethacrynic acid, furosemide, urea, or intravenous mannitol.
Overdosage: Adverse reactions specifically
associated with overdose of ARIKAYCE have not been
identified. Acute toxicity should be treated with immediate
withdrawal of ARIKAYCE, and baseline tests of renal function should
be undertaken. Hemodialysis may be helpful in removing amikacin
from the body. In all cases of suspected overdosage, physicians
should contact the Regional Poison Control Center for information
about effective treatment.
U.S. INDICATION
LIMITED POPULATION:
ARIKAYCE® is indicated in adults, who have limited
or no alternative treatment options, for the treatment
of Mycobacterium avium complex (MAC) lung disease
as part of a combination antibacterial drug regimen in patients who
do not achieve negative sputum cultures after a minimum of 6
consecutive months of a multidrug background regimen therapy. As
only limited clinical safety and effectiveness data for ARIKAYCE
are currently available, reserve ARIKAYCE for use in adults who
have limited or no alternative treatment options. This
drug is indicated for use in a limited and specific population of
patients.
This indication is approved under accelerated approval based
on achieving sputum culture conversion (defined as 3 consecutive
negative monthly sputum cultures) by Month 6. Clinical benefit has
not yet been established. Continued approval for this indication
may be contingent upon verification and description of clinical
benefit in confirmatory trials.
Limitation of Use: ARIKAYCE has only been
studied in patients with refractory MAC lung disease defined as
patients who did not achieve negative sputum cultures after a
minimum of 6 consecutive months of a multidrug background regimen
therapy. The use of ARIKAYCE is not recommended for patients with
non-refractory MAC lung disease.
Patients are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch, or
call 1–800–FDA–1088. You can also call the Company at
1-844-4-INSMED.
Please see Full Prescribing Information.
About Insmed
Insmed Incorporated is a global
biopharmaceutical company on a mission to transform the lives of
patients with serious and rare diseases. Insmed's first commercial
product is a first-in-disease therapy approved in the United
States, Europe, and Japan to treat a chronic,
debilitating lung disease. The Company is progressing a robust
pipeline of investigational therapies targeting areas of serious
unmet need, including neutrophil-mediated inflammatory diseases and
rare pulmonary disorders. Insmed is also advancing an early-stage
research engine encompassing a wide range of technologies and
modalities, including artificial intelligence-driven protein
engineering, gene therapy, and protein manufacturing. Insmed
is headquartered in Bridgewater, New
Jersey, with additional offices and research locations
throughout the United States,
Europe, and Japan. Visit www.insmed.com to learn more.
Forward-looking Statements
This press release
contains forward-looking statements that involve substantial risks
and uncertainties. "Forward-looking statements," as that term is
defined in the Private Securities Litigation Reform Act of 1995,
are statements that are not historical facts and involve a number
of risks and uncertainties. Words herein such as "may," "will,"
"should," "could," "would," "expects," "plans," "anticipates,"
"believes," "estimates," "projects," "predicts," "intends,"
"potential," "continues," and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) may identify forward-looking statements.
The forward-looking statements in this press release are based
upon the Company's current expectations and beliefs, and involve
known and unknown risks, uncertainties and other factors, which may
cause the Company's actual results, performance and achievements
and the timing of certain events to differ materially from the
results, performance, achievements or timings discussed, projected,
anticipated or indicated in any forward-looking statements. Such
risks, uncertainties and other factors include, among others, the
following: failure to obtain, or delays in obtaining, regulatory
approvals for ARIKAYCE outside the
U.S., Europe or Japan; failure to successfully
commercialize ARIKAYCE, the Company's only approved product, in the
U.S., Europe or Japan (amikacin liposome
inhalation suspension, Liposomal 590 mg Nebuliser Dispersion, and
amikacin sulfate inhalation drug product, respectively), or to
maintain U.S., European or Japanese approval for ARIKAYCE; business
or economic disruptions due to catastrophes or other events,
including natural disasters or public health crises;
uncertainties in the degree of market acceptance of ARIKAYCE
by physicians, patients, third-party payors and others in the
healthcare community; the Company's inability to obtain full
approval of ARIKAYCE from the FDA, including the risk that the
Company will not successfully or in a timely manner complete the
confirmatory post-marketing clinical trial required for full
approval of ARIKAYCE; inability of the Company, PARI or the
Company's other third-party manufacturers to comply with regulatory
requirements related to ARIKAYCE or the Lamira® Nebulizer
System; the Company's inability to obtain adequate reimbursement
from government or third-party payors for ARIKAYCE or acceptable
prices for ARIKAYCE; development of unexpected safety or efficacy
concerns related to ARIKAYCE; failure to obtain regulatory approval
to expand ARIKAYCE's indication to a broader patient
population; failure to successfully conduct future clinical
trials for ARIKAYCE due to the Company's limited experience in
conducting preclinical development activities and clinical trials
necessary for regulatory approval and its potential inability to
enroll or retain sufficient patients to conduct and complete the
trials or generate data necessary for regulatory approval, among
other things; risks that the Company's clinical studies will
be delayed or that serious side effects will be identified during
drug development; and failure of third parties on which the Company
is dependent to manufacture sufficient quantities of ARIKAYCE for
commercial or clinical needs, to conduct the Company's clinical
trials, or to comply with the Company's agreements or laws and
regulations that impact the Company's business or agreements with
the Company.
The Company may not actually achieve the results, plans,
intentions or expectations indicated by the Company's
forward-looking statements because, by their nature,
forward-looking statements involve risks and uncertainties because
they relate to events and depend on circumstances that may or may
not occur in the future. For additional information about the risks
and uncertainties that may affect the Company's business, please
see the factors discussed in Item 1A, "Risk Factors," in the
Company's Annual Report on Form 10-K for the year ended
December 31, 2022 and any subsequent
Company filings with the Securities and Exchange Commission
(SEC).
The Company cautions readers not to place undue reliance on any
such forward-looking statements, which speak only as of the date of
this press release. The Company disclaims any obligation, except as
specifically required by law and the rules of the SEC, to publicly
update or revise any such statements to reflect any change in
expectations or in events, conditions or circumstances on which any
such statements may be based, or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements.
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/insmed-announces-positive-topline-results-from-phase-3-arise-study-of-arikayce-amikacin-liposome-inhalation-suspension-in-patients-with-ntm-lung-disease-caused-by-mac-301917244.html
SOURCE Insmed Incorporated